Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom

Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” or “we”) collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included in the Company’s recent presentation. Messrs. Hacke and McIntyre have been nominated by the Group for election to Forte’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) currently scheduled for September 19, 2023.

As a reminder, the Group recently filed its own presentation that details why it believes Forte is in urgent need of boardroom change following years of poor performance and worst-in-class governance under Chairman and CEO Dr. Paul Wagner.

Michael Hacke and Chris McIntyre, the Group’s independent director candidates, commented:

“While we have been nominated by Camac and supported by ATG, we are independent and are firmly committed to acting in the best interests of all Forte stockholders and stakeholders. We believe that the Company would benefit from having independent individuals with capital allocation and investment expertise in the boardroom following the destruction of nearly 95% in stockholder value since Forte’s IPO. While it is clear to us that fresh perspectives are needed on the Board, we have no pre-set agenda or pre-conceived notions regarding Forte and would act with an open mind if elected by stockholders. Our focus would be on helping the Board improve Forte’s governance and thoroughly and objectively evaluate all options to maximize stockholder value.”

The Group encourages stockholders to consider the facts before deciding which individuals to support at the upcoming Annual Meeting:

	Forte’s Myth	The Facts
	“[…] Camac’s […] purpose is to co-opt the cash for a value potentially below the current share price and destroy value for the majority of stockholders.”	The Company is utilizing scare tactics as a defense for the Board’s indefensible poor performance and anti-stockholder actions. Forte’s equity is down nearly 95% over Drs. Wagner and Lawrence Eichenfield’s tenures. Our Group has repeatedly made clear that there needs to be accountability in the boardroom and is not demanding liquidation. Rather, we want all directors on the Board to thoroughly and objectively investigate paths to maximizing stockholder value. Our independent director candidates – Messrs. Hacke and McIntyre – are open to exploring all options to improving Forte’s performance, strategy and governance.